Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview

Nuvectis Pharma

31/07/2026 13:02

Nuvectis Pharma Inc NVCT.OQ NVCT.O is expected to  show no change in quarterly revenue when it reports  results on August 3 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Nuvectis Pharma Inc is for a loss of 26 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Nuvectis Pharma Inc is $33.00, about 45% above its last closing price of $22.76
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.31
-0.31
-0.26
Beat
16.1
Dec. 31 2026
-0.31
-0.30
-0.31
Missed
-4.2
Sep. 30 2025
-0.24
-0.25
-0.33
Missed
-33.3​
Jun. 30 2025
-0.25
-0.25
-0.30
Missed
-17.6
​​Mar. 31 2025
-0.26
-0.25
-0.27
Missed
-6.3
Dec. 31 2024
-0.25
-0.25
-0.36
Missed
-42.3​
Sep. 30 2024
-0.25
-0.25
-0.24
Beat
4.9
Jun. 30 2024
-0.26
-0.26
-0.26
Met
0
This summary was machine generated July 31 at 12:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)